Cite
Рembrolizumab as second line therapy for hepatocellular patient
MLA
I. A. Dzhanyan, et al. “Рembrolizumab as Second Line Therapy for Hepatocellular Patient.” Медицинский Совет, no. 20, Dec. 2021, pp. 150–54. EBSCOhost, https://doi.org/10.21518/2079-701X-2021-20-150-154.
APA
I. A. Dzhanyan, V. V. Breder, O. I. Borisova, & K. K. Laktionov. (2021). Рembrolizumab as second line therapy for hepatocellular patient. Медицинский Совет, 20, 150–154. https://doi.org/10.21518/2079-701X-2021-20-150-154
Chicago
I. A. Dzhanyan, V. V. Breder, O. I. Borisova, and K. K. Laktionov. 2021. “Рembrolizumab as Second Line Therapy for Hepatocellular Patient.” Медицинский Совет, no. 20 (December): 150–54. doi:10.21518/2079-701X-2021-20-150-154.